(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49ssubra) U.S. stock index e-mini futures were higher on Wednesday, setting the stage for a third straight day of gains, as oil prices rose and investors snatched up beaten-down shares. Dow Jones industrial average futures were up 0.82 percent at 16,264, S&P 500 futures were up 0.83 percent at 1,904.5 and Nasdaq 100 futures were up 1.04 percent at 4,135.5.
** KINDER MORGAN INC, Tuesday close $15.62, +12.04 pct premarket
Warren Buffett's Berkshire Hathaway Inc on Tuesday disclosed a new investment in the pipeline operator of about 26.53 million shares worth roughly $395.9 million at year end, while Leon Cooperman's Omega Advisors sold its entire stake of more than 713,000 shares.
David Tepper's Appaloosa Management hedge fund snapped up 9.4 million shares of Kinder Morgan, while Soros Fund Management took a small stake of 50,700 shares.
** FREEPORT MCMORAN INC, Tuesday close $6.37, +3.77 pct premarket
** CHENIERE ENERGY INC, Tuesday close $26.58, +1.99 pct premarket
Activist investor Carl Icahn increased his stake in Freeport McMoRan by 4 million shares to 104 million class B shares over the quarter and increased his stake in beaten-down liquefied natural gas company Cheniere by nearly 31,000 shares compared to a filing in early December.
** FOSSIL GROUP INC, Tuesday close $34.46, +12.16 pct premarket
The watch and accessories maker reported better-than-expected Q4 profit and revenue, helped by strong demand for its Fossil and Skagen brands and robust sales in Europe.
** FLEXION THERAPEUTICS INC, Tuesday close $10.9, +21.83 pct premarket
The drug developer's pain drug was found to be effective in a late-stage study, taking the company one step closer to its first ever U.S. marketing approval.
** PRICELINE GROUP INC, Tuesday close $1,110.68, +11.91 pct premarket
The travel websites operator reported a higher-than-expected quarterly profit, helped by higher hotel and rental car bookings.
** TEREX CORP, Tuesday close $20.44, +6.65 pct premarket
China's Zoomlion Heavy Industry Science and Technology Co confirmed it had made an offer for the U.S. crane maker that values the company at about $3 billion. Zoomlion is offering $30 per share to acquire Terex, or about 47 percent premium to Terex's Tuesday's close.
** INOVIO PHARMACEUTICALS INC, Tuesday close $6.57, +6.54 pct premarket
The drug developer said preclinical testing of its vaccine for Zika virus induced robust and durable response in mice and that it expected to test the vaccine in humans before the end of 2016.
** T-MOBILE US INC, Tuesday close $36.45, +4.91 pct premarket
U.S. telecom company's profit nearly tripled in the holiday quarter as aggressive price cutting and offers helped it draw customers away from competitors.
** GARMIN LTD, Tuesday close $35.23, +7.15 pct premarket
The GPS-based gadget maker reported higher-than-expected quarterly revenue, helped by strong demand for navigational devices used in aircraft and fitness trackers, and forecast full-year revenue above estimates.
** SHOPIFY INC, Tuesday close $20.5, +17.07 pct premarket
The Canadian company, which makes software that helps retailers set up online stores, forecast a 56-61 percent jump in its 2016 revenue as it adds more customers.
** CATALYST PHARMACEUTICALS INC, Tuesday close $1.85, -48.65 pct premarket
The drug developer says it got a "refusal to file" letter from FDA for Firdapse, which is being tested for the symptomatic treatment of Lambert Eaton myasthenic syndrome and congenital myasthenic syndromes.
** REGULUS THERAPEUTICS INC, Tuesday close $6.28, +41.40 pct premarket
The drug developer said interim data showed that patients tested with its hepatitis C drug combination treatment displayed sustained viral response in an ongoing mid-stage study.
** CERNER CORP, Tuesday close $55.46, -10.31 pct premarket
At least 14 brokerages cut price targets on the electronic health record provider's stock after the company disappointed investors with weak quarterly bookings and outlook. (Compiled by Subrat Patnaik in Bengaluru; Editing by Sriraj Kalluvila)